<DOC>
	<DOCNO>NCT01721967</DOCNO>
	<brief_summary>The purpose RHYME evaluate safety efficacy ranolazine Hypertrophic Cardiomypathy patient chest pain dyspnea despite treatment standard medical therapy . This small , pilot , open-label ( non-randomized ) study approve drug treatment angina novel patient population ( adult patient population hypertrophic cardiomyopathy ) .</brief_summary>
	<brief_title>Ranolazine Treatment Chest Pain HCM Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Age 18 year old Left Ventricle wall thickness &gt; /= 15mm absence condition cause hypertrophy Baseline Angina/Shortness Breath Frequency &gt; 2 episode per week Willing provide inform consent Severe stenotic valvular disease Severe valvular regurgitation except mitral regurgitation due systolic anterior motion Significant ( &gt; 60 % stenosis ) coronary artery disease Acute coronary syndrome within 30 day Severe heart failure define LV systolic dysfunction Ejection Fraction &lt; 40 % NYHA class 4 symptom Severe renal impairment ( glomerular filtration rate , &lt; 30 mL/min/1.73 m2 ) Moderatesevere hepatic impairment ( ChildPugh class B C ) Hospitalization cardiac reason within 3 month enrollment Anticipated change treatment HCM within study period , include medication , device implantation , septal reduction therapy Concomitant use ketoconazole , macrolide antibiotic , HIV protease inhibitor Active myocarditis , pericarditis , restrictive cardiomyopathy Noncardiac terminal illness expect survival less 6 month Women childbearing potential Inability perform adhere study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chest pain</keyword>
	<keyword>dyspnea</keyword>
</DOC>